Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8230543rdf:typepubmed:Citationlld:pubmed
pubmed-article:8230543lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0247342lld:lifeskim
pubmed-article:8230543lifeskim:mentionsumls-concept:C0598148lld:lifeskim
pubmed-article:8230543pubmed:issue6lld:pubmed
pubmed-article:8230543pubmed:dateCreated1993-12-10lld:pubmed
pubmed-article:8230543pubmed:abstractTextTP-40 is a hybrid fusion protein produced by recombinant technology and consists of a molecule of transforming growth factor-alpha (TGF-alpha) fused to the Pseudomonas exotoxin PE-40. A panel of human and murine bladder cancer cell lines was found to be universally sensitive in vitro to TP-40 in a clonogenic assay. All lines expressed receptor for epidermal growth factor (EGF), though none demonstrated gene amplification for the EGF receptor. The sensitivity to TP-40 may be blocked by preexposure to EGF. Six human bladder tumors taken directly from patients were all sensitive in vitro to TP-40; these included well-differentiated tumors. TP-40 may prove to be effective as an intravesical agent in bladder cancer via selective targeting to cells that express EGF receptors, as do the majority of human bladder cancers.lld:pubmed
pubmed-article:8230543pubmed:languageenglld:pubmed
pubmed-article:8230543pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230543pubmed:statusMEDLINElld:pubmed
pubmed-article:8230543pubmed:monthDeclld:pubmed
pubmed-article:8230543pubmed:issn0022-5347lld:pubmed
pubmed-article:8230543pubmed:authorpubmed-author:von HoffD DDDlld:pubmed
pubmed-article:8230543pubmed:authorpubmed-author:YeeDDlld:pubmed
pubmed-article:8230543pubmed:authorpubmed-author:SarosdyM FMFlld:pubmed
pubmed-article:8230543pubmed:authorpubmed-author:HutzlerD HDHlld:pubmed
pubmed-article:8230543pubmed:issnTypePrintlld:pubmed
pubmed-article:8230543pubmed:volume150lld:pubmed
pubmed-article:8230543pubmed:ownerNLMlld:pubmed
pubmed-article:8230543pubmed:authorsCompleteYlld:pubmed
pubmed-article:8230543pubmed:pagination1950-5lld:pubmed
pubmed-article:8230543pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:meshHeadingpubmed-meshheading:8230543-...lld:pubmed
pubmed-article:8230543pubmed:year1993lld:pubmed
pubmed-article:8230543pubmed:articleTitleIn vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity.lld:pubmed
pubmed-article:8230543pubmed:affiliationDivision of Urology and Oncology, University of Texas Health Science Center, San Antonio 78284-7845.lld:pubmed
pubmed-article:8230543pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8230543pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8230543lld:pubmed